Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

Hung Fu Tseng, Rafael Harpaz, Yi Luo, Craig M. Hales, Lina S. Sy, Sara Y. Tartof, Stephanie R. Bialek, Rulin C. Hechter, Steven J. Jacobsen

The Journal of Infectious Diseases · 2016 · 150 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated with vaccination at each year following vaccination were estimated by Cox regression model. The effectiveness of HZ vaccine decreased from 68.7% (95% CI, 66.3%-70.9%) in the first year to 4.2% (95% CI, -24.0% to 25.9%) in the eighth year. This rapid decline in effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.

References

14